Expansion of mercury-free products to replace mercury sphygmomanometers
First written in FY2016. 2 of 4 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024DroppedAnnual reportThis filing does not contain a specific disclosure on expanding mercury-free products as alternatives to mercury blood pressure monitors.
- FY2017AdvancedAnnual report
「For medical blood pressure monitors, continuing the “de-mercurization” concept from the previous fiscal year, the company developed the UM-211 medical electronic blood pressure monitor, suitable for a wide range of settings, including outpatient care, nursing and long-term care, with automatic measurement capabilities, and began domestic sales.」
The company completed development of the UM-211 medical electronic blood pressure monitor under its de-mercurization initiative and began domestic sales. - FY2017-Q3AdvancedAnnual report
「In Japan, sales of mercury-free blood pressure monitors in the medical equipment business were strong, while sales of upper-arm blood pressure monitors and ICT scales with communications capabilities were strong in the healthcare equipment business. Together with the impact of new product launches, this drove higher sales in both businesses, centered on blood pressure monitors.」
Sales of mercury-free blood pressure monitors were strong, and sales of alternative products continued to grow. - FY2016First statedAnnual report
「For medical blood pressure monitors, the company expanded the model lineup of the “Swan Heart UM-102 series” of mercury-free blood pressure monitors, which are sold as alternatives to mercury blood pressure monitors scheduled to be completely phased out in 2020 under the Minamata Convention. Unit sales increased 90% year on year and continued to perform steadily.」
Against the backdrop of the complete phaseout of mercury blood pressure monitors in 2020, the company reported an expanded alternative-product lineup and higher unit sales.